18 Jul Brentuximab Vedotin Improves Overall Survival in Treatment Naïve, Advanced Stage Hodgkin’s Lymphoma
Posted at 11:30h in Blogs 0 Comments
Brentuximab vedotin plus standard chemotherapy (B+AVD group) showed a 6-year OS of 93.9% compared to standard chemotherapy (ABVD group) 89.4% in patients with previously untreated, stage III/ IV HL. Fewer patients in the B+AVD group received subsequent therapy, including transplantation, and had fewer second cancers compared to the ABVD group. (Ref: Ansell SM et al. N Engl J Med. July 13, 2022)
Sorry, the comment form is closed at this time.